Diagnostics (Dec 2022)

Pathogenic Copy Number Variations Involved in the Genetic Etiology of Syndromic and Non-Syndromic Intellectual Disability—Data from a Romanian Cohort

  • Ioana Streață,
  • Alexandru Caramizaru,
  • Anca-Lelia Riza,
  • Simona Șerban-Sosoi,
  • Andrei Pîrvu,
  • Monica-Laura Cara,
  • Mihai-Gabriel Cucu,
  • Amelia Mihaela Dobrescu,
  • Ro-NMCA-ID Group,
  • CExBR Pediatric Neurology Obregia Group,
  • CExBR Pediatric Neurology “V. Gomoiu” Hospital Group,
  • Elena-Silvia Shelby,
  • Adriana Albeanu,
  • Florin Burada,
  • Mihai Ioana

DOI
https://doi.org/10.3390/diagnostics12123137
Journal volume & issue
Vol. 12, no. 12
p. 3137

Abstract

Read online

The investigation of unexplained global developmental delay (GDD)/intellectual disability (ID) is challenging. In low resource settings, patients may not follow a standardized diagnostic process that makes use of the benefits of advanced technologies. Our study aims to explore the contribution of chromosome microarray analysis (CMA) in identifying the genetic etiology of GDD/ID. A total of 371 Romanian patients with syndromic or non-syndromic GDD/ID, without epilepsy, were routinely evaluated in tertiary clinics. A total of 234 males (63.07%) and 137 (36.93%) females, with ages ranging from 6 months to 40 years (median age of 5.5 years), were referred for genetic diagnosis between 2015 and 2022; testing options included CMA and/or karyotyping. Agilent Technologies and Oxford Gene Technology CMA workflows were used. Pathogenic/likely pathogenic copy number variations (pCNVs) were identified in 79 patients (21.29%). Diagnosis yield was comparable between mild ID (17.05%, 22/129) and moderate/severe ID 23.55% (57/242). Higher rates were found in cases where facial dysmorphism (22.97%, 71/309), autism spectrum disorder (ASD) (19.11%, 26/136) and finger anomalies (20%, 27/96) were associated with GDD/ID. GDD/ID plus multiple congenital anomalies (MCA) account for the highest detection rates at 27.42% (17/62). pCNVs represent a significant proportion of the genetic causes of GDD/ID. Our study confirms the utility of CMA in assessing GDD/ID with an uncertain etiology, especially in patients with associated comorbidities.

Keywords